Dynavax Technologies (FRA:DYF1) Forward Dividend Yield % : 0.00% (As of Jun. 01, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Forward Dividend Yield %?

As of today (2024-06-01), the Forward Annual Dividend Yield of Dynavax Technologies is 0.00%.

As of today (2024-06-01), the Trailing Annual Dividend Yield of Dynavax Technologies is 0.00%.

FRA:DYF1's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.92
* Ranked among companies with meaningful Forward Dividend Yield % only.

Dynavax Technologies's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Dynavax Technologies's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dynavax Technologies's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Forward Dividend Yield % falls into.

Dynavax Technologies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Dynavax Technologies (FRA:DYF1) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Dynavax Technologies Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (FRA:DYF1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

DVAX:USA DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (FRA:DYF1) Headlines

No Headlines